<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00569816</url>
  </required_header>
  <id_info>
    <org_study_id>UKSHCK-Anae07/06</org_study_id>
    <secondary_id>ACA-GmbH-03-7</secondary_id>
    <nct_id>NCT00569816</nct_id>
  </id_info>
  <brief_title>Continuous Versus Repetitive Sevoflurane Administration for Preconditioning</brief_title>
  <official_title>A Comparison Between Continuous and Repetitive Sevoflurane Administration for Preconditioning During Coronary Artery Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Anaesthesiology and Intensive Care Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacologic preconditioning by volatile anesthetics may depend on the mode of
      administration. The researchers hypothesize that a continuous administration in patients
      scheduled for CABG surgery prebypass will be less effective in terms of attenuating
      myocardial cell damage compared to a repetitive administration with a double wash in/wash out
      schedule. A control group will receive propofol as their primary anesthetic.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial cell damage as assessed by plasma levels of Troponin T</measure>
    <time_frame>from induction of anesthesia until hospital discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay on the ICU and in the hospital</measure>
    <time_frame>from hospital admission until hospital discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Myocardial Injury</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol as the primary anesthetic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevoflurane administered continuously after induction of anesthesia until initiation of cardiopulmonary bypass.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevoflurane administered repetitive up to 1 MAC from induction of anesthesia until initiation of cardiopulmonary bypass. Wash in and wash out performed twice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>1 MAC Sevoflurane will be given either continuously after induction of anesthesia until initiation of cardiopulmonary bypass or will be repetitively washed in and out twice before initiation of cardiopulmonary bypass.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients schedulded to undergo CABG surgery

          -  Age 18 to 80 years

          -  Ejection fraction &gt; 40%

        Exclusion Criteria:

          -  Emergency cases

          -  Diabetes

          -  Not able to give informed consent

          -  Ejection fraction &lt; 40%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Scholz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Schleswig-Holstein, Campus Kiel, Department of Anaesthesiology and Intensive Care Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2007</study_first_submitted>
  <study_first_submitted_qc>December 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2007</study_first_posted>
  <last_update_submitted>December 6, 2007</last_update_submitted>
  <last_update_submitted_qc>December 6, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2007</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Jens Scholz</name_title>
    <organization>University Hospital Schleswig-Holstein, Campus Kiel, Department of Anaesthesiology and Intensive Care Medicine</organization>
  </responsible_party>
  <keyword>myocardial protection</keyword>
  <keyword>pharmacological preconditioning</keyword>
  <keyword>volatile anesthetics</keyword>
  <keyword>myocardial injury following CABG surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

